TABLE 2. Vaccines used to prevent hepatitis A virus (HAV) infection.
| Vaccine | Trade name (manufacturer) | Age group (yrs) | Dosage | Route | Schedule | Booster |
|---|---|---|---|---|---|---|
| Hepatitis A vaccine, inactivated |
Havrix (GlaxoSmithKline) |
1–18 |
0.5 mL (720 ELU) |
IM |
0, 6–12 mo |
None |
| ≥19 |
1 mL (1,440 ELU) |
IM |
0, 6–12 mo |
None |
||
| Hepatitis A vaccine, inactivated |
Vaqta (Merck and Co.) |
1–18 |
0.5 mL (25 U) |
IM |
0, 6–18 mo |
None |
| ≥19 |
1 mL (50 U) |
IM |
0, 6–18 mo |
None |
||
| Combined hepatitis A and B vaccine* | Twinrix (GlaxoSmithKline) | ≥18 (primary) |
1 mL (720 ELU HAV + 20 μg HBsAg) |
IM |
0, 1, 6 mo |
None |
| ≥18 (accelerated) | 1 mL (720 ELU HAV + 20 μg HBsAg) | IM | 0, 7, 21–30 days | 12 mo |
Abbreviations: ELU = ELISA units of inactivated HAV; HBsAg = hepatitis B surface antigen; IM = intramuscular; U = units of HAV antigen.
* Combined hepatitis A and B vaccine (Twinrix) should not be used for postexposure prophylaxis.